Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP

Autor:	Daniel Antunes Moreno, Howard Lopes Ribeiro Junior, Angelo Brunelli Albertoni Laranjeira, Gustavo Alencastro Veiga Cruzeiro, Kleiton Silva Borges, Karina Bezerra Salomão, Fernando Silva Ramalho, José Andres Yunes, Cleide Lúcia Araújo Silva, Eduardo Magalhães Rego, Carlos Alberto Scrideli, Luiz Gonzaga Tone
Rok vydání:	2022
Předmět:	Adult Cancer Research Mice Methotrexate Oncology Mercaptopurine Mice Inbred NOD Panobinostat Animals Humans Hematology General Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma
Zdroj:	Medical oncology (Northwood, London, England). 39(12)
ISSN:	1559-131X
Popis:	Patients diagnosed with acute lymphoblastic leukemia (ALL) bearing t(4;11)/MLL-AF4 have aggressive clinical features, poor prognosis and there is an urgent need for new therapies to improve outcomes. Panobinostat (LBH589) has been identified as a potential therapeutic agent for ALL with t(4;11) and studies suggest that the antineoplastic effects are associated with reduced MLL-AF4 fusion protein and reduced expression of HOX genes. Here, we evaluated the in vitro effects of the combination of LBH589 with methotrexate (MTX) or 6-mercaptopurine (6MP) by cell proliferation assays and Calcusyn software in ALL cell line (RS4;11); the in vivo effects of LBH589 in xenotransplanted NOD-scid IL2Rgamma
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc59f21322e631026d0453b56858e2e2 https://pubmed.ncbi.nlm.nih.gov/36175721 Zobrazit plný text záznamu Full text from SpringerLink